Evidence mapPaperPMID 41465604Full record

ArticleInternational journal of molecular sciences2025

Development of a High-Throughput Screening Platform and a Pathogenesis Model for

María-Cristina González-Montero, Julia Andrés-Rodríguez, Miguel Criado, Sonia Andrés, Giulio Galli, Celia Fernández-Rubio, Yolanda Pérez-Pertejo, Rosa M Reguera, Rafael Balaña-Fouce, Carlos García-Estrada

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development of ovine hepatic organoids: a powerfulFrontiers in veterinary science · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

María-Cristina González-MonteroDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0009-0009-1069-3940
Julia Andrés-RodríguezDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0009-0007-7191-6007
Miguel CriadoInstituto de Ganadería de Montaña, CSIC-Universidad de León, Finca Marzanas s/n, Grulleros, 24346 León, Spain.ORCID 0000-0002-0042-962X
Sonia AndrésInstituto de Ganadería de Montaña, CSIC-Universidad de León, Finca Marzanas s/n, Grulleros, 24346 León, Spain.ORCID 0000-0001-5255-1582
Giulio GalliDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0000-0001-6854-5507
Celia Fernández-RubioDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0000-0001-5254-8121
Yolanda Pérez-PertejoDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0000-0003-2361-3785
Rosa M RegueraDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0000-0001-9148-2997
Rafael Balaña-FouceDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0000-0003-0418-6116
Carlos García-EstradaDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0000-0001-5617-9669

Funding

MICIU/AEI/10.13039/501100011033 and by "ESF Investing in your future" PRE2021-096909Ministerio de Ciencia, Innovación y Universidades (MICIU)/AEI/10.13039/501100011033, "FED-ER, Una manera de hacer Europa" PID2020-119035RB-I00, PID2020-119031RB-I00, PID2021-126489OB-I00PRIMA Programme: European Union (NextGenerationEU) and Ministerio de Ciencia, In-novación y Universidades PCI2022-132925
6 · The paper itself

Abstract

The development of new alternative models is essential to overcome the limitations of traditional two-dimensional (2D) cell cultures and animal models. Three-dimensional (3D) models, such as organoids, better mimic the structural and functional complexity of mammalian organs, thereby reducing the ethical and economic issues related to animal experimentation. These systems provide more physiologically relevant environments, improving the accuracy of disease modeling and drug response prediction. In this context, we have developed mouse hepatic organoids from livers of adult BALB/c mice and characterized them by microscopy and transcriptional analysis. This model was applied to a robust and reproducible high-throughput screening (HTS) platform for testing cytotoxicity at the preclinical stage of drug discovery. In addition, mouse hepatic organoids were co-cultured with amastigotes of

Indexed as

High-Throughput Screening AssaysLeishmania donovaniLeishmaniasisLiverOrganoidsAnimalsDisease Models, AnimalHost-Parasite InteractionsMiceMice, Inbred BALB Camastigotedrug discoveryhepatic tissuehigh-throughput screeningLeishmanialiverorganoidspathogenesis model

Identifiers

PMID41465604
PMCPMC12734288

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.